AstraZeneca will remove the Goserelin 3.6 mg [1] implant, sold under the brand name Zoladex, from the Australian market later this year [1].
The withdrawal affects both the Pharmaceutical Benefits Scheme (PBS) and the private pharmacy market [1, 2]. Because the drug is used to treat critical conditions including breast cancer and endometriosis, the removal may disrupt treatment plans for patients relying on this specific dosage.
The company said the decision to pull the medication is based on commercial reasons [1]. The product is scheduled to be removed from the market in November 2026 [1].
Patients who use the 3.6 mg [1] implant will need to coordinate with their healthcare providers to find alternative treatments or different dosages before the November 2026 [1] deadline. The Goserelin implant is a key component in hormonal therapy, which suppresses the production of sex hormones to slow the growth of certain tumors, or manage the symptoms of endometriosis.
While AstraZeneca has cited commercial factors for the move, the company has not provided further details on how it will support patients during the transition. The PBS is the Australian government's program that subsidizes the cost of necessary medicines, meaning the removal of the drug from this scheme will likely increase out-of-pocket costs for those who cannot find a subsidized alternative [1, 2].
Medical professionals are expected to review patient records to identify those currently prescribed the 3.6 mg [1] dose. The shift emphasizes the vulnerability of medication supply chains when a single manufacturer decides to cease distribution of a specific product version for business reasons [1].
“AstraZeneca will remove the Goserelin 3.6 mg implant from the Australian market later this year.”
The removal of a specific dosage of Zoladex from both the public and private sectors in Australia creates a potential gap in care for patients with hormone-sensitive cancers and endometriosis. When a pharmaceutical company withdraws a drug for commercial reasons rather than safety concerns, it often signals a shift in profitability or production costs, leaving the burden of finding therapeutic alternatives on the healthcare system and the patients.
